$2.88
-0.33[-10.28%]
At close: Apr 24
$2.88
0[0.00%]
After Hours: 4:03PM EDT
Mersana Therapeutics
(NASDAQ:MRSN)Latest News for Mersana Therapeutics Stock (NASDAQ:MRSN)
Mersana Therapeutics Stock (NASDAQ: MRSN)
Categories: All
Wednesday, April 24, 2024
Tuesday, March 19, 2024
Friday, March 15, 2024
Thursday, February 29, 2024
- Mersana Therapeutics shares are trading higher after multiple analysts upgraded the stock.Benzinga Newsdesk - Feb 29, 2024, 2:18PM
- Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionAvi Kapoor - Feb 29, 2024, 2:00PM
- Hormel Foods Reports Upbeat Earnings, Joins Pure Storage, Okta, Papa John's International And Other Big Stocks Moving Higher On ThursdayAvi Kapoor - Feb 29, 2024, 11:30AM
- Expert Outlook: Mersana Therapeutics Through The Eyes Of 5 AnalystsBenzinga Insights - Feb 29, 2024, 11:00AM
- Wedbush Upgrades Mersana Therapeutics to Outperform, Raises Price Target to $7Benzinga Newsdesk - Feb 29, 2024, 10:51AM
- Truist Securities Upgrades Mersana Therapeutics to Buy, Maintains Price Target to $9Benzinga Newsdesk - Feb 29, 2024, 9:03AM
- Baird Maintains Neutral on Mersana Therapeutics, Raises Price Target to $5Benzinga Newsdesk - Feb 29, 2024, 7:17AM
- Guggenheim Upgrades Mersana Therapeutics to Buy, Announces $7 Price TargetBenzinga Newsdesk - Feb 29, 2024, 5:57AM
Wednesday, February 28, 2024
- Mersana Therapeutics shares are trading higher after the company reported Q4 financial results.Benzinga Newsdesk - Feb 28, 2024, 3:00PM
- Mersana Therapeutics Continues To Expect Capital Resources Will Support Current Operating Plan Commitments Into 2026Benzinga Newsdesk - Feb 28, 2024, 7:09AM
- Mersana Therapeutics Q4 EPS $(0.16), Inline, Sales $10.70M Miss $14.77M EstimateBenzinga Newsdesk - Feb 28, 2024, 7:02AM
- Earnings Scheduled For February 28, 2024Benzinga Insights - Feb 28, 2024, 6:24AM
Tuesday, February 27, 2024
Thursday, January 18, 2024
Friday, January 05, 2024
Monday, December 04, 2023
Tuesday, November 07, 2023
Monday, November 06, 2023
Tuesday, October 31, 2023
Wednesday, September 06, 2023
Tuesday, August 08, 2023
Friday, July 28, 2023
- Why Avantor Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day SessionLisa Levin - Jul 28, 2023, 1:07PM
- Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2023Benzinga Insights - Jul 28, 2023, 11:00AM
- Citigroup Downgrades Mersana Therapeutics to Neutral, Lowers Price Target to $1Benzinga Newsdesk - Jul 28, 2023, 9:17AM
- Baird Downgrades Mersana Therapeutics to Neutral, Lowers Price Target to $1Benzinga Newsdesk - Jul 28, 2023, 5:29AM
Thursday, July 27, 2023
- Mersana Therapeutics shares are trading lower after the company announced that the UPLIFT clinical trial of upifitamab rilsodotin did not meet its primary endpoint.Benzinga Newsdesk - Jul 27, 2023, 3:28PM
- Dow Dips Over 200 Points; McDonald's Tops Q2 ExpectationsLisa Levin - Jul 27, 2023, 2:39PM
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga Insights - Jul 27, 2023, 1:31PM
- Why Willis Towers Watson Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionLisa Levin - Jul 27, 2023, 12:53PM
- Stocks That Hit 52-Week Lows On ThursdayBenzinga Insights - Jul 27, 2023, 12:17PM
- Nasdaq Up 1%; Meta Shares Surge Following Upbeat ResultsLisa Levin - Jul 27, 2023, 12:16PM
- Why Mersana Therapeutics Stock Is Plunging Today?Vandana Singh - Jul 27, 2023, 11:23AM
- Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023Benzinga Insights - Jul 27, 2023, 11:00AM
- Wedbush Downgrades Mersana Therapeutics to Neutral, Lowers Price Target to $2Benzinga Newsdesk - Jul 27, 2023, 10:53AM
- Truist Securities Downgrades Mersana Therapeutics to HoldBenzinga Newsdesk - Jul 27, 2023, 10:52AM
- Dow Jumps 100 Points; US GDP Rises 2.4% In Q2Lisa Levin - Jul 27, 2023, 9:45AM
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga Insights - Jul 27, 2023, 9:05AM
- Mersana Therapeutics Announces UPLIFT Clinical Trial Of Upifitamab Rilsodotin Did Not Meet Primary EndpointBill Haddad - Jul 27, 2023, 7:11AM
Saturday, June 17, 2023
Friday, June 16, 2023
- What 4 Analyst Ratings Have To Say About Mersana TherapeuticsBenzinga Insights - Jun 16, 2023, 2:02PM
- Mersana Therapeutics shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral and Citigroup lowered its price target from $15 to $10. The company recently announced a partial clinical hold on two trials.Benzinga Newsdesk - Jun 16, 2023, 1:24PM
- Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2023Benzinga Insights - Jun 16, 2023, 11:01AM